Pascal Soriot on revenue target
From AstraZeneca CEO Pascal Soriot Delivers Remarks as Firm Celebrates Transfer to NYSE · · New York Stock Exchange
“This investment will help us realize our ambition to reach our 80 billion target by 2030. But the dollar number is an important one of course because you need turnover, you need profitability to be able to reinvest in R&D and we invest about 14 billion dollars in R&D today.”
On , Pascal Soriot, Chief Executive Officer & Executive Director at AstraZeneca, spoke about revenue target during AstraZeneca CEO Pascal Soriot Delivers Remarks as Firm Celebrates Transfer to NYSE on New York Stock Exchange.
About Pascal Soriot
AstraZeneca CEO Pascal Soriot spoke at the New York Stock Exchange on June 5, 2026, to mark the company's transfer to a NYSE listing. He said the move was intended to allow American investors more direct access to AstraZeneca shares and to create a harmonized global listing across New York, London, and Stockholm. Soriot described the United States as "the land of science and innovation" and said the company had committed $50 billion to expand its U.S. footprint, including manufacturing and R&D. He noted that AstraZeneca has about 25,000 employees across 23 U.S. sites. Soriot also said that "innovation in our industry is led out of this country" and that "competition with China is very fierce," adding that "Europe is falling back." On AstraZeneca's Q1 2026 earnings call on April 30, Soriot reported that total revenue grew 8% and operating profit increased 12%, driven by demand for innovative medicines. He highlighted that COPD "remains a critical area of unmet medical need" and that the company is seeking accelerated approval for a drug in that area, which he said could reach blockbuster potential. Soriot also discussed the company's pipeline, expressing confidence in extending growth beyond 2030 and reiterating an ambition to reach an $80 billion revenue target by that year.